Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …

Background Assessing safety and efficacy of Covid-19 vaccines in different populations is
essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern …

Background COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate
of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before …

COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct
SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from …

Accumulating evidence supports the use of higher doses of rifampicin for tuberculosis (TB)
treatment. Rifampicin is a potent inducer of metabolic enzymes and drug transporters, …

In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses
of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-…

Background: Covid-19 vaccine rollout is lagging in Africa, where there has been a high
force of SARS-CoV-2 infection. We evaluated the effect of SARS-CoV-2 infection prior to …